Neuropeptides
Volume 41, Issue 1 , Pages 51-58 , February 2007

The role of neuropeptide FF (NPFF) in the expression of sensitization to hyperlocomotor effect of morphine and ethanol

  • Jolanta Kotlinska

      Affiliations

    • Department of Pharmacology and Pharmacodynamics, Medical University, Staszica Str. 4, 20-081 Lublin, Poland
    • Corresponding Author InformationCorresponding author. Tel.: +48 81 5328927; fax: +48 81 5328903.
    • ,
  • Agnieszka Pachuta

      Affiliations

    • Department of Pharmacology and Pharmacodynamics, Medical University, Staszica Str. 4, 20-081 Lublin, Poland
    • ,
  • Tomasz Dylag

      Affiliations

    • Faculty of Chemistry and Regional Laboratory, Jagiellonian University, Krakow, Poland
    • ,
  • Jerzy Silberring

      Affiliations

    • Faculty of Chemistry and Regional Laboratory, Jagiellonian University, Krakow, Poland

Received 26 May 2006 ,Accepted 15 September 2006.

References 

  1. Allard M, Geoffre S, Legendre P, Vincent JD, Simonnet G. Characterization of rat spinal cord receptors to FLFQPQRF amide, a mammalian morphine modulating peptide: a binding study. Brain Res. 1989;500:169–176
  2. Allard M, Zajac JM, Simonnet G. Autoradiographic distribution of receptors to FLFQPQRF amide, a morphine-modulating peptide, in rat central nervous system. Neuroscience. 1992;49:101–116
  3. Attila M, Kurkijarvi U, Kivipelto L, Panula P, Ahtee L. The antiopioid peptide, neuropeptide FF, enhances the effects of acute morphine on the cerebral monoamines in rats. Pharmacol. Res. 1995;32:293–298
  4. Babbini M, Davis WM. Time–dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br. J. Pharmacol. 1972;46:213–224
  5. Ballet S, Mauborgne A, Gouarderes C, Bourgoin AS, Hamon M, Zajac J-M, et al. The neuropeptide FF analogue, 1DME, enhances in vivo met-enkephalin release from the rat spinal cord. Neuropharmacology. 1999;38:1317–1324
  6. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Rev. 1998;28:309–369
  7. Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, et al. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J. Biol. Chem. 2000;275:39324–39331
  8. Cador M, Marco N, Stinus L, Simonnet G. Interaction between neuropeptide FF and opioids in the ventral tegmental area in the behavioral response to novelty. Neuroscience. 2002;110:309–318
  9. Cesselin F. Opioid and anti-opioid pepides. Fundam. Clin. Pharmacol. 1995;9:409–443
  10. Chen JC, Li JY, Liang KW, Huang YK. Neuropeptide FF potentiates the behavioral sensitization to amphetamine and alters the levels of neurotransmitters in the medial prefrontal cortex. Brain Res. 1999;816:220–224
  11. Chen JC, Lee W-H, Chen P-C, Tseng C-P, Huang EY-K. Rat NPFF1 receptor-mediated signaling: functional comparison of neuropeptide FF (NPFF), FMRFamide and PFR(Tic)amide. Peptides. 2006;27:1005–1014
  12. Del Rosario CN, Pacchioni AM, Cancela LM. Influence of acute or repeated restraint stress on morphine-induced locomotion: involvement of dopamine, opioid and glutamate receptors. Behav. Brain Res. 2002;134:229–238
  13. Devillers JP, Boisserie F, Laulin JP, Larcher A, Simonnet G. Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Brain Res. 1995;700:173–181
  14. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J. Neurosci. 2002;22:6747–6755
  15. Gouarderes C, Sutek M, Zajac J-M, Jhamandas K. Antinociceptive effects of intrathecall administerd F8Famide and FMR-Famide in the rat. Eur. J. Pharmacol. 1993;237:73–81
  16. Herz A. Endogenous opioid system and alcohol addiction. Psychopharmacology. 1997;129:99–111
  17. Joyce EM, Iversen SD. The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat. Neurosci. Lett. 1979;14:207–212
  18. Kalivas PW, Duffy P. Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J. Pharmacol. Exp. Ther. 1987;241:204–212
  19. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 1991;16:223–244
  20. Kavaliers M. Inhibitory influences of mammalian FMRFamide (Phe-Met-Arg-Phe-amide)-related peptides on nociception and morphine- and stress-induced analgesia in mice. Neurosci. Lett. 1990;115:307–312
  21. Kavaliers M, Yang H-Y. IgG from antiserum against endogenous mammalian FMRF-NH2-related peptides augments morphine- and stress-induced analgesia in mice. Peptides. 1989;10:741–745
  22. Koetzner L, Hua XY, Lai J, Porreca F, Yaksh T. Nonopioid actions of intrathecal dynorphin evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and -2. J. Neurosci. 2004;24:1451–1458
  23. Kokkinnidis L, Zacharo RM. Enhanced self-stimulation responding from the substantia nigra after chronic amphetamine treatment: a role for conditioning factors. Pharmacol. Biochem. Behav. 1980;12:543–547
  24. Kotani M, Mollereau C, Detheux M, Le Poul E, Brezillon S, Vakili J, et al. Functional characterization of a human receptor for neuropeptide FF and related peptides. Br. J. Pharmacol. 2001;133:138–144
  25. Kotlinska J, Bochenski M, Danysz W. N-methyl-d-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice. Behav Pharmacol. 2006;17:1–8
  26. Kuribara H. Modification of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice. Eur. J. Pharmacol. 1995;275:251–258
  27. Kuribara H. Induction of sensitization to hyperactivity caused by morphine in mice: effects of post-drug environments. Pharmacol. Biochem. Behav. 1997;57:341–346
  28. Laursen SE, Belknap JK. Intracerebroventricular injections in mice. Some methodological refinements. J. Pharmacol. Meth. 1986;16:355–357
  29. Lessov CN, Phillips TJ. Duration of sensitization to the locomotor stimulant effects of ethanol in mice. Psychopharmacology. 1998;135:374–382
  30. Liu Q, Guan XM, Martin WJ, McDonald TP, Clements MK, Jiang Q, et al. Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J. Biol. Chem. 2001;276:36961–36969
  31. Majanem EA, Yang HY. FMRF-NH2-like peptide is deficient in the pituitary gland of the Brattleboro rat. Peptides. 1990;11:345–349
  32. Majane EA, Zhu J, Aarnisalo AA, Panula P, Yang HY. Origin of neurohypophyseal neuropeptide-FF (FLFQPQRF-NH2). Endocrinoogy. 1993;133:1578–1584
  33. Malin DH, Lake JR, Fowler DE, Hammond MV, Brown SL, Leyva JE, et al. FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides. 1990;11:277–280
  34. Marchand S, Betourne A, Marty V, Daumas S, Halley H, Lassalle JM, et al. A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides. 2006;27:964–972
  35. Marco N, Stinus L, Allard M, Le Moal M, Simonnet G. Neuropeptide FLFQRFamide receptors within the ventral mesencephalon and dopaminergic terminal areas: localization and functional antiopioid involvement. Neuroscience. 1995;64:1035–1044
  36. Mauborgne A, Bourgoin S, Polienor H, Roumy M, Simonnet G, Zajac JM, et al. The neuropeptide FF analogue, 1DMe, acts as a functional opioid autoreceptor antagonist in the rat spinal cord. Eur. J. Pharmacol. 2001;430:273–276
  37. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science. 1997;278:58–63
  38. Ng GY, O’Dowd BF, George SR. Genotypic differences in mesolimbic enkephalin gene expression in DBA/2J and C57BL/6J inbred mice. Eur. J. Pharmacol. 1996;311:45–52
  39. Panula P, Aarnisalo AA, Wasowicz K. Neuropeptide FF, a mammalian neuropeptide with multiple functions. Prog. Neurobiol. 1996;48:461–487
  40. Panula P, Kalso E, Nieminen M, Kontinen VK, Brandt A, Pertovaara A. Neuropeptide FF and modulation of pain. Brain Res. 1999;848:191–196
  41. Piazza PV, Deminiere JM, le Moal M, Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res. 1990;514:22–26
  42. Raffa RB, Kim A, Rice KC, de Costa BR, Codd EE, Rothman RB. Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8- amide (NPFF) and A-18-Famide, for opioid mu, delta, kappa 1, kappa 2a, or kappa 2b receptors. Peptides. 1994;15:401–404
  43. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 1986;396:157–198
  44. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 1993;18:247–291
  45. Rothman RB. review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse. 1992;12:129–138
  46. Rothman RB, Brady LS, Xu H, Long JB. Chronic intraventricular infusion of the anti-opiod peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain. Peptides. 1993;14:1271–1277
  47. Roumy M, Zajac JM. Neuropeptide FF, pain and analgesia. Eur. J. Pharmacol. 1998;345:1–11
  48. Segal DS, Kuczenski R. Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res. 1992;577:351–355
  49. Segal DS, Mandell AJ. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol. Biochem. Behav. 1974;2:249–255
  50. Shippenberg TS, Heidbreder C, Lefevour A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. Eur. J. Pharmacol. 1996;299:33–39
  51. Simonin F, Schmitt M, Laulin JP, Laboureyras E, Jhamandas JH, MacTavish D, et al. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc. Natl. Acad. Sci. USA. 2006;103:466–471
  52. Spanagel R, Shippenberg TS. Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat. Neurosci. Lett. 1993;153:232–236
  53. Stewart J, Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav. Pharmacol. 1993;4:289–312
  54. Stinus L, Allard M, Gold L, Simonnet G. in CNS neuropeptide FF-like material, pain sensitivity, and opiate dependence following chronic morphine treatment. Peptides. 1995;16:1235–1241
  55. Tang J, Yang HY, Costa E. Inhibition of spontaneous and opiate mediated nociception by an andogenous neuropeptide with Phe-Met-Arg-Phe-NH2-like immunoreactivity. Proc. Natl. Acad. Sci. USA. 1984;81:5002–5005
  56. Vezina P, Kalivas PW, Stewart J. Sensitization occurs to the locomotor effects of morphine and the specific mu opioid receptor agonist, DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens. Brain Res. 1987;417:51–58
  57. Walaas I. Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience. 1981;6:399–405
  58. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987;94:469–492
  59. Wolf ME, Jeziorski M. Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization. Brain Res. 1993;613:291–294
  60. Wolf ME, Dahlin SL, Hu XT, Xue CJ, White K. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: comparison with N-methyl-d-aspartate antagonists. Neuroscience. 1995;69:417–439
  61. Yang HY, Martin RM. Isolation and characterization of a neuropeptide FF-like peptide from brain and spinal cord of rat. Soc. Neurosci. Abstr. 1995;21:760
  62. Yang HY, Fratta W, Majane EA, Costa E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc. Natl. Acad. Sci. USA. 1985;82:7757–7761

PII: S0143-4179(06)00115-6

doi: 10.1016/j.npep.2006.09.048

Neuropeptides
Volume 41, Issue 1 , Pages 51-58 , February 2007

Article Tools

* Image Usage & Resolution